A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Olaparib|DRUG: Carboplatin|DRUG: Anthracycline|DRUG: Cyclophosphamide
Sponsor: AstraZeneca